首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2116篇
  免费   91篇
  国内免费   88篇
耳鼻咽喉   29篇
儿科学   110篇
妇产科学   24篇
基础医学   342篇
口腔科学   41篇
临床医学   268篇
内科学   460篇
皮肤病学   37篇
神经病学   77篇
特种医学   320篇
外科学   187篇
综合类   32篇
一般理论   2篇
预防医学   75篇
眼科学   15篇
药学   112篇
肿瘤学   164篇
  2023年   4篇
  2022年   8篇
  2021年   19篇
  2020年   15篇
  2019年   34篇
  2018年   25篇
  2017年   19篇
  2016年   29篇
  2015年   33篇
  2014年   26篇
  2013年   58篇
  2012年   52篇
  2011年   71篇
  2010年   75篇
  2009年   73篇
  2008年   68篇
  2007年   109篇
  2006年   85篇
  2005年   76篇
  2004年   58篇
  2003年   60篇
  2002年   73篇
  2001年   56篇
  2000年   63篇
  1999年   50篇
  1998年   105篇
  1997年   94篇
  1996年   119篇
  1995年   94篇
  1994年   94篇
  1993年   77篇
  1992年   31篇
  1991年   37篇
  1990年   34篇
  1989年   41篇
  1988年   41篇
  1987年   32篇
  1986年   45篇
  1985年   37篇
  1984年   22篇
  1983年   24篇
  1982年   21篇
  1981年   23篇
  1980年   18篇
  1979年   7篇
  1978年   9篇
  1977年   17篇
  1976年   16篇
  1975年   8篇
  1965年   2篇
排序方式: 共有2295条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Five patients with idiopathic transient osteoporosis were examined. Bone scanning and MRI was helpful in the diagnosis to differentiate of necrosis and all patients recovered completely with conservative and symptomatic treatment. There was no history of trauma in all patients. MRI was realized previously in all cases to confirm the diagnosis and after the resolution of symptomathology.  相似文献   
6.
Poly(epsilon-caprolactone) microspheres containing bupivacaine were prepared by the spray-drying process. The average size of drug loaded microspheres was less than 3 microm in diameter, and the percentage of entrapment efficiency was 91 +/- 3%. In vitro drug release kinetic in phosphate buffer at 37 degrees C showed a hyperbolic profile, with a burst-effect during the first hour. Subcutaneous injection of bupivacaine-loaded microspheres in the back of rats caused an increase in drug concentration in plasma. Maximum bupivacaine concentration in plasma was 237 +/- 58 ng/ml at 105 h, and drug was detected in plasma for 16 days. The half-life time of the drug was increased by more than 125 times with regard to that of the drug administered in a solution by intraperitoneal injection. After 30 days of injection, a mass formed by microspheres surrounded by a thin fibrous capsule was observed. Small blood vessels and multinucleate foreign body giant cells with macrophagic function around microspheres were detected. After 60 days of injection a subcutaneous mass was also observed, which was formed of more degraded dispersed microspheres in conjunctive tissue, which had a normal structure. Thus, bupivacaine-loaded poly(epsilon-caprolactone) microspheres could be considered as a device to be used in the treatment of severe pain that is not responsive to opioids for example in cancer-related syndromes or in intractable herpetic neuralgia.  相似文献   
7.
8.
9.
Pharmacokinetics and tissue penetration of netilmicin were studied after the use of a single dose (6 mg/kg) given for antibioprophylaxis in colo-rectal surgery. Thirteen patients, scheduled for elective surgery, were given 6 mg/kg IV netilmicin over 30 min, together with 1000 mg IV ornidazole. Netilmicin peak serum concentration (10 min after end of infusion) was 24.4 +/- 3.4 mg/l and trough level (24 h) was 0.9 +/- 0.5 mg/l. Plasma elimination half-life was 409 +/- 70 min, le volume apparent volume of distribution was 38 +/- 101 and total body clearance was 0.07 +/- 0.02 ml/min. Adequate netilmicin levels (5 greater than or equal to CMI 90 of involved pathogens Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus) were obtained in 100 per cent of patients in abdominal wall and epiploid fat, at time of opening, and in colonic wall at time of anastomosis. Adequate levels were obtained at time of closure in abdominal wall and epiploid fat in 92 to 100 per cent of patients. In situation of allergy to beta-lactam antibiotics, the use of netilmicin in combination with ornidazole may be recommended.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号